Date
- Monday, 04 April 2011
Location
- European Medicines Agency, Amsterdam, the Netherlands
The objective of the meeting is to discuss the clinical development of new drugs for the treatment of chronic hepatitis C in the paediatric population, taking into consideration possible differences between the adult and paediatric population in particular in terms of safety and possibility to extrapolate efficacy from the adult data.